序号

2025年7月我校24篇热点论文

标题

来源期刊

DOI

Research Field

Times Cited

1

MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES

JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024

10.1002/jev2.12404

BIOLOGY & BIOCHEMISTRY

1009

2

GLOBAL BURDEN OF 288 CAUSES OF DEATH AND LIFE EXPECTANCY DECOMPOSITION IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 2100-2132 MAY 18 2024

10.1016/S0140-6736(24)00367-2

CLINICAL MEDICINE

527

3

GLOBAL INCIDENCE, PREVALENCE, YEARS LIVED WITH DISABILITY (YLDS), DISABILITY-ADJUSTED LIFE-YEARS (DALYS), AND HEALTHY LIFE EXPECTANCY (HALE) FOR 371 DISEASES AND INJURIES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 2133-2161 MAY 18 2024

10.1016/S0140-6736(24)00757-8

CLINICAL MEDICINE

494

4

GLOBAL BURDEN AND STRENGTH OF EVIDENCE FOR 88 RISK FACTORS IN 204 COUNTRIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 2162-2203 MAY 18 2024

10.1016/S0140-6736(24)00933-4

CLINICAL MEDICINE

453

5

CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY

LANCET 402 (10408): 1133-1146 SEP 30 2023

10.1016/S0140-6736(23)00961-3

CLINICAL MEDICINE

309

6

OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC

NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023

10.1056/NEJMoa2304594

CLINICAL MEDICINE

251

7

GLOBAL AGE-SEX-SPECIFIC MORTALITY, LIFE EXPECTANCY, AND POPULATION ESTIMATES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1950-2021, AND THE IMPACT OF THE COVID-19 PANDEMIC: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 1989-2056 MAY 18 2024

10.1016/S0140-6736(24)00476-8

CLINICAL MEDICINE

208

8

BURDEN OF DISEASE SCENARIOS FOR 204 COUNTRIES AND TERRITORIES, 2022-2050: A FORECASTING ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 2204-2256 MAY 18 2024

10.1016/S0140-6736(24)00685-8

CLINICAL MEDICINE

189

9

GUIDELINES FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS B (VERSION 2022)

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY 11 (6): 1425-1442 NOV 2023

10.14218/JCTH.2023.00320

CLINICAL MEDICINE

171

10

AGGREGATION-INDUCED EMISSION (AIE), LIFE AND HEALTH

ACS NANO 17 (15): 14347-14405 JUL 24 2023

10.1021/acsnano.3c03925

MATERIALS SCIENCE

163

11

ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER

NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024

10.1056/NEJMoa2310532

CLINICAL MEDICINE

118

12

GLOBAL, REGIONAL, AND NATIONAL BURDEN OF STROKE AND ITS RISK FACTORS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET NEUROLOGY 23 (10): 973-1003 OCT 2024

10.1016/S1474-4422(24)00369-7

NEUROSCIENCE & BEHAVIOR

106

13

PHOTOTHERMAL THERAPY OF TUBERCULOSIS USING TARGETING PRE-ACTIVATED MACROPHAGE MEMBRANE-COATED NANOPARTICLES

NATURE NANOTECHNOLOGY 19 (6): - JUN 2024

10.1038/s41565-024-01618-0

MATERIALS SCIENCE

101

14

GLOBAL FERTILITY IN 204 COUNTRIES AND TERRITORIES, 1950-2021, WITH FORECASTS TO 2100: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021

LANCET 403 (10440): 2057-2099 MAY 18 2024

10.1016/S0140-6736(24)00550-6

CLINICAL MEDICINE

97

15

THE CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO): CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF GASTRIC CANCER, 2023

CANCER COMMUNICATIONS : - DEC 31 2023

10.1002/cac2.12516

CLINICAL MEDICINE

96

16

USING CLUSTERPROFILER TO CHARACTERIZE MULTIOMICS DATA

NATURE PROTOCOLS 19 (11): - NOV 2024

10.1038/s41596-024-01020-z

BIOLOGY & BIOCHEMISTRY

93

17

GLOBAL BURDEN OF METABOLIC DISEASES, 1990-2021021

METABOLISM-CLINICAL AND EXPERIMENTAL 160: - NOV 2024

10.1016/j.metabol.2024.155999

BIOLOGY & BIOCHEMISTRY

52

18

BEST: A WEB APPLICATION FOR COMPREHENSIVE BIOMARKER EXPLORATION ON LARGE-SCALE DATA IN SOLID TUMORS

JOURNAL OF BIG DATA 10 (1): - NOV 1 2023

10.1186/s40537-023-00844-y

COMPUTER SCIENCE

51

19

SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS THE ASSOCIATION BETWEEN HISTONE LACTYLATION AND CISPLATIN RESISTANCE IN BLADDER CANCER

DRUG RESISTANCE UPDATES 73: - MAR 2024

10.1016/j.drup.2024.101059

PHARMACOLOGY & TOXICOLOGY

50

20

RHIZOMA DRYNARIAE-DERIVED NANOVESICLES REVERSE OSTEOPOROSIS BY POTENTIATING OSTEOGENIC DIFFERENTIATION OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS VIA TARGETING ERA SIGNALING

ACTA PHARMACEUTICA SINICA B 14 (5): 2210-2227 MAY 2024

10.1016/j.apsb.2024.02.005

PHARMACOLOGY & TOXICOLOGY

21

21

HARNESSING THE TUMOR MICROENVIRONMENT: TARGETED CANCER THERAPIES THROUGH MODULATION OF EPITHELIAL-MESENCHYMAL TRANSITION

JOURNAL OF HEMATOLOGY & ONCOLOGY 18 (1): - JAN 13 2025

10.1186/s13045-024-01634-6

CLINICAL MEDICINE

14

22

TRANSARTERIAL CHEMOEMBOLISATION COMBINED WITH LENVATINIB PLUS PEMBROLIZUMAB VERSUS DUAL PLACEBO FOR UNRESECTABLE, NON-METASTATIC HEPATOCELLULAR CARCINOMA (LEAP-012) : A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY

LANCET 405 (10474): 203-215 JAN 18 2025

10.1016/S0140-6736(24)02575-3

CLINICAL MEDICINE

9

23

IMLGAM: INTEGRATED MACHINE LEARNING AND GENETIC ALGORITHM-DRIVEN MULTIOMICS ANALYSIS FOR PAN-CANCER IMMUNOTHERAPY RESPONSE PREDICTION

IMETA 4 (2): - APR 2025

10.1002/imt2.70011

MICROBIOLOGY

8

24

RAPID DISCRIMINATION AND RATIO QUANTIFICATION OF MIXED ANTIBIOTICS IN AQUEOUS SOLUTION THROUGH INTEGRATIVE ANALYSIS OF SERS SPECTRA VIA CNN COMBINED WITH NN-EN MODEL

JOURNAL OF ADVANCED RESEARCH 69: 61-74 MAR 2025

10.1016/j.jare.2024.03.016

CHEMISTRY

7